Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.
Clinical Trials Arena on MSN
Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC
"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by ...
The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.
Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio ...
Different subsets of γδ T cells display differential expression of immune checkpoint receptors (ICRs) and have distinct ...
The Poco F8 Ultra has a 6.9-inch OLED display, which Poco calls HyperRGB - their 'full RGB subpixel structure' does appear to ...
The FDA has granted fast track designation (FTD) to AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback